We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
+4.03%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$155M
AUM Growth
+$8.11M
Cap. Flow
+$10.2M
Cap. Flow %
6.57%
Top 10 Hldgs %
70.21%
Holding
70
New
6
Increased
8
Reduced
6
Closed
3

Top Buys

Rank Stock Value
1
ELUT icon
Elutia
ELUT
+$8.01M
2
INBX
Inhibrx, Inc. Common Stock
INBX
+$1.6M
3
BDSX icon
Biodesix
BDSX
+$965K
4
TSVT
2seventy bio
TSVT
+$873K
5
NBIX icon
Neurocrine Biosciences
NBIX
+$828K

Top Sells

Rank Stock Value
1
XLRN
Acceleron Pharma
XLRN
+$1.84M
2
BMY icon
Bristol-Myers Squibb
BMY
+$1.76M
3
BLUE
bluebird bio
BLUE
+$539K
4
BIOR
Biora Therapeutics, Inc. Common Stock
BIOR
+$410K
5
VNDA icon
Vanda Pharmaceuticals
VNDA
+$349K

Sector Composition

Rank Sector Weight
1 Healthcare 96.09%
2 Energy 2.08%
3 Consumer Staples 0.21%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
STOK icon
51
Stoke Therapeutics
STOK
$1.72B
$360K 0.23%
15,000
– –
KNSA icon
52
Kiniksa Pharmaceuticals
KNSA
$4.81B
$353K 0.23%
30,000
– –
SILK
53
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$341K 0.22%
+8,000
New +$400K
IFRX icon
54
InflaRx
IFRX
$268M
$333K 0.21%
70,000
– –
TGTX icon
55
TG Therapeutics
TGTX
$8.36B
$285K 0.18%
15,000
– –
BCRX icon
56
BioCryst Pharmaceuticals
BCRX
$2.34B
$277K 0.18%
20,000
– –
ISEE
57
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$251K 0.16%
15,000
– –
PFE icon
58
Pfizer
PFE
$141B
$236K 0.15%
+4,000
New +$198K
LSF icon
59
Laird Superfood
LSF
$47.1M
$235K 0.15%
18,000
+4,000
+29% +$61.8K
AKBA icon
60
Akebia Therapeutics
AKBA
$341M
$226K 0.15%
100,000
– –
AWH
61
DELISTED
Aspira Women's Health Inc. Common Stock
AWH
$182K 0.12%
6,874
– –
ELTX icon
62
Elicio Therapeutics
ELTX
$79.8M
$158K 0.1%
5,439
– –
SIEN
63
DELISTED
Sientra, Inc.
SIEN
$147K 0.09%
4,000
– –
DCGO icon
64
DocGo
DCGO
$66.8M
$94K 0.06%
+10,000
New +$92.8K
YTEN
65
DELISTED
Yield10 Bioscience, Inc. Common Stock
YTEN
$92K 0.06%
781
-2
-0.3% -$264
CNCE
66
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$63K 0.04%
20,000
– –
TXMD icon
67
TherapeuticsMD
TXMD
$24M
$18K 0.01%
1,000
-1,000
-50% -$30K
ARQT icon
68
Arcutis Biotherapeutics
ARQT
$3.49B
– –
-9,000
Closed -$215K
BIOR
69
DELISTED
Biora Therapeutics, Inc. Common Stock
BIOR
– –
-1,080
Closed -$410K
XLRN
70
DELISTED
Acceleron Pharma
XLRN
– –
-10,672
Closed -$1.84M
1 2
3

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q4 2021 Portfolio in Review

As of Q4 2021, Birchview Capital held 70 positions worth $155M, up 5.5% from $147M the previous quarter. Its ten largest holdings account for 70% of the portfolio.

Birchview Capital deployed $10.2M of net new capital in Q4 2021, opening 6 new positions and adding to 8 existing holdings. Its largest new stake was Inhibrx, Inc. Common Stock: 40,000 shares worth $1.75M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 96% a quarter earlier, followed by Energy and Consumer Staples.

On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $1.76M trimmed.

  • Birchview Capital's largest Q4 2021 buy was Inhibrx, Inc. Common Stock: 40,000 shares worth $1.75M.
  • Birchview Capital added most to Elutia in Q4 2021, an estimated $8.01M increase.
  • Birchview Capital's biggest Q4 2021 reduction was Bristol-Myers Squibb, cutting an estimated $1.76M.
  • Birchview Capital fully exited Acceleron Pharma in Q4 2021, selling an estimated $1.84M.
  • Birchview Capital's ten largest holdings make up 70% of its $155M portfolio in Q4 2021.
  • Birchview Capital opened 6 new positions and closed 3 in Q4 2021.
  • Birchview Capital's portfolio value rose 5.5% quarter-over-quarter to $155M.

Based on Birchview Capital's 13F filing for Q4 2021, filed 14 Feb 2022.